HCV kinetic and modeling analyses indicate similar time to cure among sofosbuvir combination regimens with daclatasvir, simeprevir or ledipasvir

• Harel Dahari,
• Laetitia Canini,
• Frederik Graw,
• Susan L. Uprichard,
• EvaldoS A. Araujo,
• Guillaume Penaranda,
• Emilie Coquet,
• Aurélie Riso,
• Christophe Renou,
• Marc Bourlière,
• Scott J. Cotler,
• Philippe Halfon

Affiliations

Harel Dahari

Loyola University Medical Center, Division of Hepatology, The Program for Experimental & Theoretical Modeling, Maywood, Illinois, USA; Theoretical Biology & Biophysics Group, Los Alamos National Laboratory, Los Alamos, New Mexico, USA

Laetitia Canini

Loyola University Medical Center, Division of Hepatology, The Program for Experimental & Theoretical Modeling, Maywood, Illinois, USA; University of Edinburgh, Center for Immunity, Infection and Evolution, Edinburgh, UK

Frederik Graw

Heidelberg University, Center for Modeling and Simulation in the Biosciences, BioQuant Center, Heidelberg, Germany

Susan L. Uprichard

Loyola University Medical Center, Division of Hepatology, The Program for Experimental & Theoretical Modeling, Maywood, Illinois, USA

EvaldoS A. Araujo

University of Sao Paulo Hospital das Clinicas, Sao Paulo, Brazil

Guillaume Penaranda

Alphabio Laboratory, Marseille, France

Emilie Coquet

Alphabio Laboratory, Marseille, France

Aurélie Riso

Saint Joseph Hospital, Division of Hepatology, Marseille, France

Christophe Renou

Hyeres Hospital, Division of Hepatology, Hyeres, France

Marc Bourlière

Saint Joseph Hospital, Division of Hepatology, Marseille, France

Scott J. Cotler

Loyola University Medical Center, Division of Hepatology, The Program for Experimental & Theoretical Modeling, Maywood, Illinois, USA

Philippe Halfon

Alphabio Laboratory, Marseille, France; European Hospital, Internal Medicine and Infectious Disease, Marseille, France